Trial Profile
A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms CA209-9EM
- 06 May 2022 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 06 May 2022 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 16 Jun 2021 Planned End Date changed from 1 Apr 2022 to 1 Sep 2023.